« Back to Record
Citation APA

Buisseret, L., Loirat, D., Aftimos, P., Maurer, C., Punie, K., Debien, V., Kristanto, P., Eiger, D., Goncalves, A., Ghiringhelli, F., Taylor, D., Clatot, F., Van den Mooter, T., Ferrero, J. M., Bonnefoi, H., Canon, J.-L., Duhoux, F. P., Mansi, L., Poncin, R., Barthélémy, P., Isambert, N., Denis, Z., Catteau, X., Salgado, R., Agostinetto, E., de Azambuja, E., Rothé, F., Craciun, L., Venet, D., Romano, E., Stagg, J., Paesmans, M., Larsimont, D., Sotiriou, C., Ignatiadis, M., & Piccart-Gebhart, M. (2023). Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial. Nature communications, 14(1), 7018. doi:10.1038/s41467-023-42744-y


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/366857

Buisseret, L., Loirat, D., Aftimos, P., Maurer, C., Punie, K., Debien, V., Kristanto, P., Eiger, D., Goncalves, A., Ghiringhelli, F., Taylor, D., Clatot, F., Van den Mooter, T., Ferrero, J. M., Bonnefoi, H., Canon, J.-L., Duhoux, F. P., Mansi, L., Poncin, R., Barthélémy, P., Isambert, N., Denis, Z., Catteau, X., Salgado, R., Agostinetto, E., de Azambuja, E., Rothé, F., Craciun, L., Venet, D., Romano, E., Stagg, J., Paesmans, M., Larsimont, D., Sotiriou, C., Ignatiadis, M., & Piccart-Gebhart, M. (2023). Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial. Nature communications, 14(1), 7018. doi:10.1038/s41467-023-42744-y